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Personalised reimbursement: a risk-sharing
model for biomarker-driven treatment of
rare subgroups of cancer patients
Precision medicine in oncology is based on the premise that every
tumour is unique and therefore requires a thorough molecular
analysis to identify the best possible targeted treatment. In gen-
eral, access to precision medicine, especially outside an approved
indication is challenging. There are several barriers and concerns.
Although the paradigm of precision medicine in cancer is to tar-
get a specific genetic aberration, there is uncertainty regarding ef-
fectiveness for every biomarker–tumour–drug combination.
Various other factors, such as post-transcriptional modifications,
protein expression, tissue context, heterogeneity of the tumour
and its microenvironment, variations in patient characteristics,
and prior treatments also contribute to uncertainty of treatment
outcome.
Collecting data and generating evidence on off-label use are
complex outside a clinical trial. Randomised clinical trials are dif-
ficult to conduct as small numbers of patients carry a particular
genetic aberration in a specific tumour type. Clinical evidence is
therefore mostly based on case-studies or small single-armed tri-
als. Historical data are often not available to compare treatment
outcome to conventional treatment, as earlier studies have not al-
ways taken the genetic make-up of the tumour into account.
However, regulatory agencies have developed tools (e.g. condi-
tional market authorisation or accelerated approvals) to address
this problem and facilitate timely access to the patient.
An illustrative example of the latter is the accelerated approval
of the checkpoint inhibitor pembrolizumab for adult and paedi-
atric patients with unresectable or metastatic, microsatellite
instability-high (MSI-H) or mismatch repair deficient (dMMR)
advanced solid tumours that have progressed following prior
treatment and who have no satisfactory alternative treatment op-
tion. The U.S. Food and Drug Administration (FDA) approval
was tissue/site-agnostic and based on retrospective analysis of
data from 149 patients, including 90 patients with metastatic co-
lorectal cancer (mCRC), across 5 single-arm clinical trials [1].
MSI-H tumours are rare and their prevalence varies widely
among tumour types. Bonneville et al. [2] detected MSI-H with a
prevalence >1% in 12 out of the 39 different types of cancers,
which severely hampers the execution of adequately powered
randomised trials.
In June 2017, the application of another checkpoint inhibitor,
nivolumab, for MSI-H or dMMR mCRC patients with the
European Medicines Agency (EMA) was withdrawn as the evi-
dence presented to the EU Committee for Medicinal Products for
Human Use (CHMP) at the EMA was considered insufficient.
Major concerns were the non-comparative design of the pivotal
study, the limited number of patients (n¼ 74), the absence of
overall survival data, and high discordance between local and cen-
tral MSI testing. In addition, CHMP had concerns regarding the
placing of nivolumab in second line (after prior fluoropyrimidine-
based therapy), in the absence of convincing evidence and with sev-
eral established treatment options are available [3].
In the Netherlands, a non-randomised, multi-centre basket
trial, The Drug Rediscovery Protocol (DRUP) [4], is active to
specifically identify signals of clinical benefit of approved drugs
used outside their label in rare, molecularly defined subsets of
patients who have exhausted standard-of-care treatment options.
The trial also contains an MSI cohort in which patients with MSI-
H tumours are treated with nivolumab, irrespective of their tu-
mour type (with the exception of approved indications). The
results of this cohort of 30 patients are in line with the retrospec-
tive data used for the FDA accelerated approval of pembrolizu-
mab, further underlining the efficacy of checkpoint inhibitors in
patients with these tumours.
Currently, as the MSI-H cohort of the DRUP trial has reached
target recruitment and is therefore closed, newly diagnosed
patients in the Netherlands have no access to treatment. There is
also no coverage by health insurers for this biomarker-driven in-
dication with promising data. This poses a serious dilemma and
it is likely that other anticancer agents with high antitumour ac-
tivity in non-randomised studies will encounter similar barriers.
As a consequence, there is a growing need for a learning health
care model which enables early access to potentially effective ther-
apies, where no other established treatment options are available,
without overestimating the findings that are based on small
cohorts of patients. Continuous monitoring to enrich a real-
world database is essential for this learning model.
In the Netherlands, the government determines the content of
the standard health insurance package that covers necessary
healthcare costs. Subsequently, this package is offered by all
insurers. The government is advised by the National Health Care
Institute (Zorginstituut Nederland), an independent health tech-
nology assessment (HTA) authority that evaluates interventions,
to ensure that the standard health insurance package is cost-
effective, evidence-based, and in accordance with state of the art
and state of the practice. In some cases, the health insurers can de-
cide to reimburse drugs which are not included in the package,
for instance, when a disease is extremely rare (prevalence <1/
150 000) and no other treatment option is available [5].
The Dutch government regularly negotiates price/volume
agreements for drugs with a high budget impact. The immune
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checkpoint inhibitors have also been subjected to confidential na-
tional price agreements. However, off-label use of expensive
drugs is usually not covered by payers. As the health care budget
is limited and there is a continuous rise in expenditure, the payers
are obliged to allocate their budgets reasonably and responsibly.
This presents a dilemma, especially when clear clinical benefit is
seen in a small patient population such as MSI-H patients. In the
case of MSI-H, the Health Insurers in the Netherlands and the
National Health Care Institute acknowledge the medical need in
patients who have exhausted other treatment options. This
prompted us to collaborate in developing a personalised
decision-making model to enable early access to potentially effec-
tive therapies whilst being aware of the increased pressure on the
health care budget.
Here, we present a performance-based, personalised reim-
bursement scheme that enables access to precision medicine in
rare biomarker-defined subgroups. In the Netherlands, this
scheme will be an integral part of the ongoing DRUP trial. In this
trial, eligible patients for a particular tumour–drug combination
are recruited based on Simon’s two-stage design approach. Eight
patients are enrolled in stage I and 16 more in stage II, if more
than 1 response is observed in the first stage. If less than five
patients show an objective tumour response or stable disease at
16 weeks, the cohort is closed (Figure 1). However, when the sec-
ond stage is successful with five or more patients benefitting from
the therapy, the cohort will be expanded to a third stage, with de-
fined inclusion criteria, duration of treatment and number of
patients needed to confirm the initial results. The first two stages
of the DRUP trial are exploratory, with medication considered to
be investigational medicinal products provided for free by the
marketing authorisation holder (MAH). The third stage is
designed to confirm the findings in the first and second stages
and can be partly reimbursed based on a pay for performance
model. In this model, patients start on treatment with the investi-
gational medicinal product as provided by the MAH and con-
tinue on the regular drug product which is reimbursed in case of
adequate individual treatment response. Adequate response is
defined as complete remission or partial remission based on
RECIST 1.1 (or iRECIST for in case of ICI) at 16 weeks or pro-
longed stable disease (at least 16 weeks but duration can vary
depending on tumour–drug combinations).
Although this model provides access to potentially effective
drugs for patients without other treatment options and allows
risk-sharing between the manufacturer and payers, there are
some considerations and limitations:
1. The manufacturers are needed to partner in this approach by
providing investigational medicinal product for free until a
meaningful clinical response is achieved at 16 weeks.
2. Payers and HTA authorities need to approve the model, pref-
erably by embracing general rules of the proposed scheme. In
fact, the presented scheme is a result of close collaboration
among medical oncologists, National Health Care Institute,
and health insurers in the Netherlands, all of whom support
this model.
3. A molecular tumour board, which consists of a multidiscipli-
nary team of experts, should evaluate molecular and clinical
data and provide recommendations on inclusion in the DRUP
study.
4. The patient should be notified of the experimental nature of
the treatment and provide consent, and also to allow further
(translational) research.
5. As the magnitude of benefit on overall survival and quality of
life is unclear, it is important to periodically analyse the
results. The structure of a clinical trial with predefined num-
ber of patients, pre-planned interim analysis, and futility
assessments can save resources.
6. It is important to gather biomarker data that can be used to
further refine patient selection in the future and hence im-
prove quality of care.
7. Nationwide, patients need to have equal access to the treat-
ment and treatment evaluations need to be harmonised.
8. The necessity of the continuation of the performance-based
reimbursement scheme should regularly be evaluated based
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Figure 1. A performance-based, personalised reimbursement scheme after 16weeks of clinical benefit at stage III, when the effectiveness is
proven for an individual patient, commercial medication will be reimbursed by payers.
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9. Organisation of such personalised reimbursement schemes is
complex in terms of infrastructure and administrative burden.
The performance-based reimbursement scheme that we pro-
pose here will run as a pilot, using the infrastructure of the DRUP
trial. By integrating into the current infrastructure of the DRUP
trial, through expanding the trial to a third stage, we will guaran-
tee careful data-management and uniform genomic and MSI
testing and evaluation. This stepwise approach can be used in the
future for other rare molecular subgroups.
To our knowledge, this is the first time that a risk-sharing model
has been set up between pharmaceutical industry and payers for
biomarker-driven, tissue-independent, cancer treatment. The
learning health care scheme proposed here allows patients with
various tumour types to have early access to potentially effective
off-label drugs based on their specific molecular profile, while at
the same time real-world evidence for precision medicine is gener-
ated. In the pilot, to be run in the Netherlands, the performance-
based reimbursement step will run alongside the national financial
agreements with manufacturers to ensure responsible use of
health care resources. This model can be a step forward in deliver-
ing precision medicine in a sustainable and affordable manner.
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Enthuse for PERUSE: when clinical
judgment overcomes regulatory boundaries
Contemporary treatment of human epidermal growth factor
2 (HER2)-positive breast cancers is a successful example of the ra-
tionale development of molecularly targeted therapies. The ob-
servation that HER2 overexpression or gene amplification was
associated with more aggressive phenotype and poorer prognosis
has laid the groundwork for developing agents to antagonize this
pathway [1].
The humanized monoclonal anti-HER2 antibody trastuzumab
combined with cytotoxic agents was rapidly established as the
standard therapy of early and advanced HER2-positive breast
cancer in light of its unquestionable efficacy [2–5]. But this
was just the beginning. Indeed, metastatic breast cancer is still
incurable. The importance of maintaining the inhibition of
the pathway has been demonstrated across further lines of anti-
HER2-based therapies speeding up the development of new
HER2-targeted agents including lapatinib, pertuzumab and T-
DM1 [6–8]. The appealing synergy of dual anti-HER2 targeting
fully revealed its clinical value in the Clinical Evaluation of
Pertuzumab and Trastuzumab study (CLEOPATRA). In this
trial, the addition of pertuzumab to trastuzumab and docetaxel
as first-line therapy resulted, among other things, in a 15.7-
month overall survival improvement [9–11]. The results of
the CLEOPATRA trial led to regulatory approval of pertuzumab–
trastuzumab and docetaxel as first-line therapy for HER2-
positive advanced breast cancer patients.
Despite EMA and FDA labels including docetaxel as the che-
motherapy backbone, in routine oncology practice, paclitaxel is
often preferred in the metastatic setting because of its more favor-
able safety profile.
Annals of Oncology Editorials
Volume 30 | Issue 5 | 2019 doi:10.1093/annonc/mdz091 | 665
